Thermochemical ablation of bodily tissue

• US 8,926,586 B2
• Filed: 11/15/2013
• Issued: 01/06/2015
• Est. Priority Date: 02/27/2007
• Status: Active Grant

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Cressman, Erik N. K.
• Primary Examiner(s): STIGELL, THEODORE J
• Application Number:
  US14/081,001
• Publication Number:
  US 20140074063A1
• Time in Patent Office: 417 Days
• Field of Search: 604/82, 604/257, 604/506, 606/27, 600/410
• US Class Current: 604/506
• CPC Class Codes: A61B 18/06 caused by chemical reaction , e.g. moxaburners
• CPC Class Codes: A61B 2018/00577 Ablation
• CPC Class Codes: A61B 2018/068 none of the reactants being oxygen

Abstract

Thermochemical ablation techniques may provide ablation of bodily tissue using chemical reaction energy.

Claims

1. A method for thermochemical ablation of a liver cancer tumor of a liver, comprising:

delivering a first thermochemical ablation liquid comprising an acid solution through a first lumen of a percutaneous injection cannula to at least a first exterior port along an exterior of a distal portion of the injection cannula positioned within the liver cancer tumor while simultaneously delivering a second thermochemical ablation liquid comprising a base solution through a second lumen of the percutaneous injection cannula to at least a second exterior port along the exterior of the distal portion positioned within the liver cancer tumor, the second thermochemical ablation liquid being reactive with the first thermochemical ablation liquid; and

causing the first and second thermochemical ablation liquids to disperse and mix within the liver cancer tumor proximate to the distal portion of the injection cannula positioned within the liver cancer tumor so that the first and second thermochemical ablation liquids mix with one another to generate heat from an exothermic chemical reaction that is sufficient to ablate at least a portion of the liver cancer tumor.

2. The method of claim 1, wherein the first and second thermochemical ablation liquids mix with one another to generate the exothermic chemical reaction while substantially eliminating an acid load applied to the liver from the first thermochemical ablation liquid.

3. The method of claim 2, wherein the first and second thermochemical ablation liquids mix with one another to generate the exothermic chemical reaction while substantially eliminating a base load applied to the liver from the second thermochemical ablation liquid.

4. The method of claim 1, wherein the first thermochemical ablation liquid comprises the acid solution including an acid selected from the group consisting of acetic acid, peracetic acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, nitrous acid, perchloric acid, phosphoric acid, oxalic acid, pyruvic acid, malonic acid, and amino acids.

5. The method of claim 4, wherein the second thermochemical ablation liquid comprises the base solution including a base selected from the group consisting of KOH, NaOH, NH4OH, Ca(OH)2, NaHCO3, K2CO2, BuLi, NaOEt or NaSEt, NaH, KH, and amines.

6. The method of claim 1, wherein the second thermochemical ablation liquid remains isolated from the first thermochemical ablation liquid before exiting from the second exterior port of the injection cannula.

7. The method of claim 6, wherein the first and second thermochemical ablation liquids mix with one another external from the distal portion of the injection cannula positioned with the liver cancer tumor to generate the heat sufficient to ablate said at least a portion of the liver cancer tumor.

8. The method of claim 1, further comprising monitoring in real-time using a medical imaging system the distal portion of the injection cannula positioned with the liver cancer tumor while simultaneously delivering the first and second thermochemical ablation liquids.

9. The method of claim 1, wherein the first and second exterior ports comprise side ports along the exterior of the injection cannula that provide radial dispersion of the first and second thermochemical ablation liquids.

10. The method of claim 1, wherein said simultaneously delivering the first and second thermochemical ablation liquids into the liver cancer tumor comprises simultaneously adjusting a first actuator configured to act upon the first thermochemical ablation liquid and a second actuator configured to act upon the second thermochemical ablation liquid, the first and second actuators being mechanically coupled to one another.

11. The method of claim 1, wherein said causing the first and second thermochemical ablation liquids to disperse and mix within the liver cancer tumor provides salt byproducts from the mixing of the acid solution and the base solution, the salt byproducts being hyperosmolar at a level sufficient to produce a local environment within the liver cancer tumor that incompatible with cell survival in the liver cancer tumor after the heat is dissipated.

12. The method of claim 1, wherein said at least a portion of the liver cancer tumor is ablated by the heat from the exothermic reaction and without using an RF ablation instrument.

13. The method of claim 1, wherein said percutaneous injection cannula comprises a percutaneous injection needle having a generally rigid needle shaft.

14. The method of claim 13, wherein the generally rigid needle shaft of the percutaneous injection needle has an outer diameter of about 0.135 inches or less.

15. The method of claim 14, wherein the generally rigid needle shaft of the percutaneous injection needle comprises stainless steel.

16. The method of claim 14, wherein the distal portion of the percutaneous injection needle includes a pointed tip so as to facilitate penetration through skin and toward the liver cancer tumor.

17. The method of claim 1, wherein said percutaneous injection cannula comprises a catheter having a flexible catheter body.

18. The method of claim 17, wherein the flexible catheter body is configured to advance through a body vessel toward the liver cancer tumor.

19. The method of claim 17, wherein the catheter includes a steering mechanism to navigate the distal portion of the catheter through the body vessel toward the liver cancer tumor.

20. The method of claim 17, wherein the flexible catheter body is equipped with magnetic resonance markers to provide viewability using a medical imaging system.